DNLI
Price
$18.27
Change
+$0.16 (+0.88%)
Updated
Jan 14 closing price
Capitalization
2.85B
46 days until earnings call
Intraday BUY SELL Signals
PRQR
Price
$1.64
Change
-$0.00 (-0.00%)
Updated
Jan 14 closing price
Capitalization
172.77M
35 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

DNLI vs PRQR

Header iconDNLI vs PRQR Comparison
Open Charts DNLI vs PRQRBanner chart's image
Denali Therapeutics
Price$18.27
Change+$0.16 (+0.88%)
Volume$1.13M
Capitalization2.85B
ProQR Therapeutics
Price$1.64
Change-$0.00 (-0.00%)
Volume$611.97K
Capitalization172.77M
DNLI vs PRQR Comparison Chart in %
DNLI
Daily Signal:
Gain/Loss:
PRQR
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
DNLI vs. PRQR commentary
Jan 15, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DNLI is a Hold and PRQR is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jan 15, 2026
Stock price -- (DNLI: $18.27 vs. PRQR: $1.64)
Brand notoriety: DNLI and PRQR are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: DNLI: 72% vs. PRQR: 114%
Market capitalization -- DNLI: $2.85B vs. PRQR: $172.77M
DNLI [@Biotechnology] is valued at $2.85B. PRQR’s [@Biotechnology] market capitalization is $172.77M. The market cap for tickers in the [@Biotechnology] industry ranges from $114.05B to $0. The average market capitalization across the [@Biotechnology] industry is $2.27B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

DNLI’s FA Score shows that 0 FA rating(s) are green whilePRQR’s FA Score has 1 green FA rating(s).

  • DNLI’s FA Score: 0 green, 5 red.
  • PRQR’s FA Score: 1 green, 4 red.
According to our system of comparison, both DNLI and PRQR are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

DNLI’s TA Score shows that 4 TA indicator(s) are bullish while PRQR’s TA Score has 4 bullish TA indicator(s).

  • DNLI’s TA Score: 4 bullish, 5 bearish.
  • PRQR’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, both DNLI and PRQR are a bad buy in the short-term.

Price Growth

DNLI (@Biotechnology) experienced а +7.79% price change this week, while PRQR (@Biotechnology) price change was -24.07% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.31%. For the same industry, the average monthly price growth was +3.20%, and the average quarterly price growth was +43.69%.

Reported Earning Dates

DNLI is expected to report earnings on Mar 02, 2026.

PRQR is expected to report earnings on Feb 19, 2026.

Industries' Descriptions

@Biotechnology (+0.31% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
DNLI($2.85B) has a higher market cap than PRQR($173M). DNLI YTD gains are higher at: 10.660 vs. PRQR (-18.812). PRQR has higher annual earnings (EBITDA): -38.15M vs. DNLI (-534.17M). DNLI has more cash in the bank: 848M vs. PRQR (107M). PRQR has less debt than DNLI: PRQR (16.5M) vs DNLI (44.4M). PRQR has higher revenues than DNLI: PRQR (15.5M) vs DNLI (0).
DNLIPRQRDNLI / PRQR
Capitalization2.85B173M1,649%
EBITDA-534.17M-38.15M1,400%
Gain YTD10.660-18.812-57%
P/E RatioN/AN/A-
Revenue015.5M-
Total Cash848M107M793%
Total Debt44.4M16.5M269%
FUNDAMENTALS RATINGS
DNLI vs PRQR: Fundamental Ratings
DNLI
PRQR
OUTLOOK RATING
1..100
958
VALUATION
overvalued / fair valued / undervalued
1..100
94
Overvalued
25
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9799
PRICE GROWTH RATING
1..100
4990
P/E GROWTH RATING
1..100
99100
SEASONALITY SCORE
1..100
5085

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

PRQR's Valuation (25) in the Biotechnology industry is significantly better than the same rating for DNLI (94). This means that PRQR’s stock grew significantly faster than DNLI’s over the last 12 months.

PRQR's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as DNLI (100). This means that PRQR’s stock grew similarly to DNLI’s over the last 12 months.

DNLI's SMR Rating (97) in the Biotechnology industry is in the same range as PRQR (99). This means that DNLI’s stock grew similarly to PRQR’s over the last 12 months.

DNLI's Price Growth Rating (49) in the Biotechnology industry is somewhat better than the same rating for PRQR (90). This means that DNLI’s stock grew somewhat faster than PRQR’s over the last 12 months.

DNLI's P/E Growth Rating (99) in the Biotechnology industry is in the same range as PRQR (100). This means that DNLI’s stock grew similarly to PRQR’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
DNLIPRQR
RSI
ODDS (%)
N/A
Bullish Trend 1 day ago
87%
Stochastic
ODDS (%)
Bearish Trend 3 days ago
86%
Bullish Trend 1 day ago
85%
Momentum
ODDS (%)
Bullish Trend 3 days ago
78%
Bearish Trend 1 day ago
86%
MACD
ODDS (%)
Bullish Trend 3 days ago
86%
Bearish Trend 1 day ago
85%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
77%
Bearish Trend 1 day ago
84%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
73%
Bearish Trend 1 day ago
83%
Advances
ODDS (%)
Bullish Trend 3 days ago
76%
Bullish Trend 9 days ago
84%
Declines
ODDS (%)
Bearish Trend 11 days ago
82%
Bearish Trend 3 days ago
84%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
81%
Bullish Trend 1 day ago
90%
Aroon
ODDS (%)
Bearish Trend 3 days ago
83%
Bearish Trend 1 day ago
86%
View a ticker or compare two or three
Interact to see
Advertisement
DNLI
Daily Signal:
Gain/Loss:
PRQR
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
GTCIX21.280.22
+1.04%
Glenmede Disciplined International EqPtf
BSCRX20.230.20
+1.00%
Brandes Small Cap Value R6
AASMX24.620.18
+0.74%
Thrivent Small Cap Stock A
FFGAX23.99N/A
N/A
Fidelity Advisor Global Commodity Stk A
TRLGX83.79-1.34
-1.57%
T. Rowe Price Lrg Cp Gr I

DNLI and

Correlation & Price change

A.I.dvisor indicates that over the last year, DNLI has been loosely correlated with RGNX. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if DNLI jumps, then RGNX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DNLI
1D Price
Change %
DNLI100%
+0.88%
RGNX - DNLI
54%
Loosely correlated
-0.66%
BEAM - DNLI
53%
Loosely correlated
+2.49%
SYRE - DNLI
52%
Loosely correlated
+5.17%
CDXS - DNLI
51%
Loosely correlated
+4.09%
NRIX - DNLI
50%
Loosely correlated
+0.58%
More

PRQR and

Correlation & Price change

A.I.dvisor indicates that over the last year, PRQR has been loosely correlated with RGNX. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if PRQR jumps, then RGNX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PRQR
1D Price
Change %
PRQR100%
N/A
RGNX - PRQR
49%
Loosely correlated
-0.66%
BEAM - PRQR
46%
Loosely correlated
+2.49%
RNAC - PRQR
44%
Loosely correlated
-0.26%
ETHZ - PRQR
44%
Loosely correlated
+5.05%
DNLI - PRQR
44%
Loosely correlated
+0.88%
More